ASH News Daily 2017 - Issue 3 - B-22

Page B-22

ASH News Daily

Monday, December 11, 2017

career-

enhancemenT
awardS

ASH Scholars
«« From Page B-16

will enable her to further study the
DNA damage response in leukemia
stem cells.
Craig Byersdorfer, MD, PhD
Dr. Byersdorfer is an assistant
professor at the Children's Hospital
of Pittsburgh. He
completed undergraduate studies
at the University
of Minnesota and
earned his MD
and PhD degrees
from Washington
University in St.
Louis,
followed
by residency and
fellowship training at the University of Michigan. During fellowship,
he worked with Dr. James Ferrara
to study the role of immune cell metabolism during graft-versus-host
disease (GVHD), making the seminal discovery that GVHD-causing T
cells adopt alternative forms of metabolism, including an increased reliance on the oxidation of fat. He has
expanded on these studies to further investigate both the drivers of
fat oxidation in alloreactive T cells,
as well as to elucidate the role of additional metabolic proteins during
GVHD development. With his ASH
Scholar Award, Dr. Byersdorfer will
continue his investigations into the
biology of the cellular energy sensor AMP-activated protein kinase
(AMPK), paying particular attention to the post-transplantation behavior of regulatory T cells which
lack AMPK and the role of AMPK
in human T cells. Dr. Byersdorfer is
honored to be chosen as a recipient
of this award and is thankful for the
critical support and timely recognition at this early stage of his career.
Shuaiying Cui, PhD
Dr. Cui is an assistant professor in
the Department of Medicine at Boston University School of Medicine.
He received his
PhD in 2006 from
the University of
Science and Technology of China. Dr. Cui then
joined the University of Michigan
as a postdoctoral
fellow in the Department of Internal Medicine where he studied
viral vector-based gene therapy. In
2010, Dr. Cui began his work under

Dr. James Douglas Engel's supervision, working toward the development of a molecular intervention
therapy for sickle cell disease. Dr.
Cui's research has focused on the
development of novel agents that
can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells
and progenitors through a series of
epigenetic chromatin modifications
by nucleosome remodeling, histone
deacetylation, and demethylation.
Such agents can be applied to the
treatment of the patients with hematologic disorders such as sickle
cell disease and beta-thalassemia,

as well as acute myeloid leukemia,
which arise from congenital defects in the genome. The findings
from these preclinical studies could
also help to establish therapeutic
indications in other hematologic
malignancies. Dr. Cui is playing
a leading role for his team in their
ongoing sickle cell disease-related
research projects supported by the
ASH Scholar Award.
Jarrod Dudakov, PhD
Dr. Dudakov is an assistant
member in the Clinical Research
Division at the Fred Hutchinson
Cancer Research Center and an as-

sistant professor
in the Department
of
Immunology
at the University
of
Washington.
He received his
PhD working in
the laboratory of
Dr. Richard Boyd
at Monash University in Melbourne, Australia,
and went on to complete postdoctoral training under Dr. Marcel van
den Brink at MSKCC in New York.
Notwithstanding its importance
»» ASH SCHOLARS Page B-23

NOW APPROVED FOR THE TREATMENT OF
CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN
NEWLY DIAGNOSED AND RELAPSED/REFRACTORY PATIENTS1
TM

MYLOTARG™ (gemtuzumab ozogamicin) is indicated for the treatment of:
u Newly diagnosed CD33-positive AML in adults
u Relapsed/refractory CD33-positive AML in adults and pediatric patients
2 years and older
IMPORTANT SAFETY INFORMATION
WARNING: Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also
known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use
of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor
frequently for signs and symptoms of VOD after treatment with MYLOTARG.
Hepatotoxicity, Including Veno-occlusive Liver Disease (VOD): An increased risk of VOD was
observed in patients with moderate/severe hepatic impairment and patients who received
MYLOTARG either before or after HSCT. Assess ALT, AST, total bilirubin, and alkaline phosphatase
prior to each dose of MYLOTARG. After treatment with MYLOTARG, monitor frequently for signs
and symptoms of VOD; these may include elevations in ALT, AST, and total bilirubin, hepatomegaly,
rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk
of VOD. For patients who develop abnormal liver tests, more frequent monitoring of liver tests
and clinical signs and symptoms of hepatotoxicity is recommended. For patients who proceed to
HSCT, monitor liver tests frequently during the post-HSCT period, as appropriate. Manage signs
or symptoms of hepatic toxicity by dose interruption or discontinuation of MYLOTARG. In patients
who experience VOD, discontinue MYLOTARG and treat according to standard medical practice.
Infusion-Related Reactions (Including Anaphylaxis): Life-threatening or fatal infusion-related
reactions can occur during or within 24 hours following infusion of MYLOTARG. Signs and
symptoms of infusion-related reactions may include fever, chills, hypotension, tachycardia,
hypoxia, and respiratory failure. Premedicate prior to MYLOTARG infusion. Monitor vital signs
frequently during infusion. Interrupt infusion immediately for patients who develop evidence of
infusion reaction, especially dyspnea, bronchospasm, or hypotension. Monitor patients during and
for at least 1 hour after the end of the infusion or until signs and symptoms completely resolve.
Discontinue use of MYLOTARG in patients who develop signs or symptoms of anaphylaxis,
including severe respiratory symptoms or clinically significant hypotension.
Hemorrhage: MYLOTARG is myelosuppressive and can cause fatal or life-threatening hemorrhage
due to prolonged thrombocytopenia. Assess blood counts prior to each dose of MYLOTARG and
monitor blood counts frequently after treatment with MYLOTARG until resolution of cytopenias.
Monitor patients for signs and symptoms of bleeding during treatment with MYLOTARG. Manage
severe bleeding, hemorrhage, or persistent thrombocytopenia using dose delay or permanent
discontinuation of MYLOTARG, and provide supportive care per standard practice.

F:7.625"

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 3